Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320908 | 1.00 | CCR5 (0.41) | CCR5TAS1R3TAS1R1NTRK1EPHX2 | |
| SCHEMBL13041366 | 0.88 | MAPK1 (0.35) | CCR5TAS1R3TAS1R1TSHRMAPK1 | |
| SCHEMBL2967446 | 0.88 | MAPK1 (0.35) | CCR5TAS1R3TAS1R1TSHRMAPK1 | |
| SCHEMBL2967424 | 0.85 | PSEN1 (0.42) | CCR5EPHX2MAPK1MMP2MMP3 | |
| SCHEMBL8320239 | 0.85 | PSEN1 (0.42) | CCR5EPHX2MAPK1MMP2MMP3 | |
| SCHEMBL2958400 | 0.84 | MMP1 (0.35) | CCR5MAPK1MMP2MMP1MMP9 | |
| SCHEMBL5489292 | 0.84 | MMP1 (0.35) | CCR5MAPK1MMP2MMP1MMP9 | |
| SCHEMBL8312713 | 0.84 | MMP1 (0.35) | CCR5MAPK1MMP2MMP1MMP9 | |
| SCHEMBL8317885 | 0.83 | KEAP1 (0.37) | MAPK1CCNA2CDK2CCNA1MMP2 | |
| SCHEMBL2956506 | 0.83 | KEAP1 (0.37) | MAPK1CCNA2CDK2CCNA1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511267-A1 | 3-((N-ACYLATED AMINOACYL)AMINO)PYRAZOLES AS INHIBITORS OF BETA-AMYLOID PEPTIDE PRODUCTION USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | claimed |
| EP-2511267-A1 | 3-((N-ACYLATED AMINOACYL)AMINO)PYRAZOLES AS INHIBITORS OF BETA-AMYLOID PEPTIDE PRODUCTION USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1633350-A4 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARM INC (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| EP-1633350-A2 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005009344-A2 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | APP, BACE1, APH1A | CCR5 4721/4885TAS1R3 1446/4885TAS1R1 1666/4885 |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | APP, BACE1, APH1A | CCR5 4721/4885TAS1R3 1446/4885TAS1R1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.